Association of host genetic risk factors with the course of cytomegalovirus retinitis in patients infected with human immunodeficiency virus

American Journal of Ophthalmology

Volumn 151, Issue 6, 2011, Pages

  Sezgin, Efe ^a   Van Natta, Mark L ^b   Ahuja, Alka ^b   Lyon, Alice ^c   Srivastava, Sunil ^d   Troyer, Jennifer L ^e   O'Brien, Stephen J ^a   Jabs, Douglas A ^b,f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SAIC FREDERICK INC   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 10 RECEPTOR; STROMAL CELL DERIVED FACTOR 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; CYTOMEGALOVIRUS RETINITIS; DISEASE COURSE; DRUG EFFICACY; EUROPEAN AMERICAN; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RETINA DETACHMENT; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79957559681     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.11.029     Document Type: Article

References (59)

1. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992;166(6):1223-1227.
2. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996;114(7):821-827. (Pubitemid 26240529)
3. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 1995;93:623-683.
4. Pertel P, Hirschtick R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992;5(11):1069-1074.
5. Studies of Ocular Complications of AIDS (LSOCA) Research Group ACTGA. Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. Control Clin Trials 1992;13(1):22-39.
6. Thorne JE, Jabs DA, Kempen JH, et al. Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology 2006;113(8):1441-1445. (Pubitemid 44108167)
7. Thorne JE, Jabs DA, Kempen JH, et al. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology 2006;113(8):1432- 1440. (Pubitemid 44108166)
8. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997. AIDS 1998;12(14):1931-1933. (Pubitemid 28454463)
9. Jabs DA. AIDS and ophthalmology, 2008. Arch Ophthalmol 2008;126(8):1143-1146.
10. Jabs DA, Holbrook JT, Van Natta ML, et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2005;112(5):771-779. (Pubitemid 40631495)
11. Jabs DA, Van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology 2007;114(4):780-786.
12. Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunningham ET. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(1):231-233. (Pubitemid 30067103)
13. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-860. (Pubitemid 28135961)
14. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology 2004;111(12):2224-2231.
15. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology 2004;111(12):2232-2239.
16. Johnson SC, Benson CA, Johnson DW, Weinberg A. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis 2001;32(5):815-819. (Pubitemid 32221942)
17. Komanduri KV, Feinberg J, Hutchins RK, et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 2001;183(8):1285-1289. (Pubitemid 32281571)
18. Torriani FJ, Freeman WR, Macdonald JC, et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 2000;14(2):173-180.
19. Jabs DA, Ahuja A, Natta MV, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes. Ophthalmology 2010;117(11):2152-2161.
20. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004;36(6):565-574. (Pubitemid 38715980)
21. Tang J, Kaslow RA. The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. AIDS 2003;17(Suppl 4):S51-60.
22. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273(5283):1856-1862. (Pubitemid 26322495)
23. Hendrickson SL, Jacobson LP, Nelson GW, et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. J Acquir Immune Defic Syndr 2008;48(3):263-271.
24. Kasten S, Goldwich A, Schmitt M, et al. Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients. Eur J Med Res 2000;5(8):323-328.
25. O'Brien TR, McDermott DH, Ioannidis JP, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000;14(7):821-826. (Pubitemid 30303459)
26. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277(5328):959-965. (Pubitemid 27366682)
27. Bogner JR, Lutz B, Klein HG, et al. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Med 2004;5(4):264-272. (Pubitemid 39077118)
28. Puissant B, Roubinet F, Massip P, et al. Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts. AIDS Res Hum Retroviruses 2006;22(2):153-162. (Pubitemid 43277151)
29. Wit FW, van Rij RP, Weverling GJ, Lange JM, Schuite-maker H. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. J Infect Dis 2002;186(12):1726-1732. (Pubitemid 35463504)
30. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998;282(5395):1907-1911.
31. Garcia-Moruja C, Rueda P, Torres C, et al. Molecular phenotype of CXCL12beta 3′UTR G801A polymorphism (rs1801157) associated to HIV-1 disease progression. Curr HIV Res 2009;7(4):384-389.
32. Lathey JL, Tierney C, Chang SY, et al. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis 2001;184(11):1402-1411. (Pubitemid 33108854)
33. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998;279(5349):389-393.
34. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A 2000;97(4):1695-1700. (Pubitemid 30118505)
35. Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002;2(11):831-844. (Pubitemid 37328706)
36. Sezgin E, Jabs DA, Hendrickson SL, et al. Effect of host genetics on the development of cytomegalovirus retinitis in patients with AIDS. J Infect Dis 2010;202(4):606-613.
37. Jabs DA, Van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. Ophthalmology 2007;114(4):787-793.
38. Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Stat Med 1994;13(21):2233-2247. (Pubitemid 24343234)
39. An P, Martin MP, Nelson GW, et al. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS 2000;14(14):2117-2122.
40. Brambilla A, Villa C, Rizzardi G, et al. Shorter survival of SDF1-3′A/3′A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis 2000;182(1):311-315. (Pubitemid 30497821)
41. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998;12(9):F85-90.
42. Daar ES, Lynn HS, Donfield SM, et al. Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression. J Infect Dis 2005;192(9):1597-1605. (Pubitemid 41504695)
43. Spencer JV, Lockridge KM, Barry PA, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 2002;76(3):1285-1292. (Pubitemid 34066432)
44. Vink C, Beisser PS, Bruggeman CA. Molecular mimicry by cytomegaloviruses. Function of cytomegalovirus-encoded homologues of G protein-coupled receptors, MHC class I heavy chains and chemokines. Intervirology 1999;42(5-6):342-349.
45. Davis MG, Kenney SC, Kamine J, Pagano JS, Huang ES. Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc Natl Acad Sci U S A 1987;84(23):8642-8646. (Pubitemid 18033466)
46. Margalith M, D'Aquila RT, Manion DJ, et al. HIV-1 DNA in fibroblast cultures infected with urine from HIV-seropositive cytomegalovirus (CMV) excretors. Arch Virol 1995;140(5):927-935.
47. McKeating JA, Griffiths PD, Weiss RA. HIV susceptibility conferred to human fibroblasts by cytomegalovirus-induced Fc receptor. Nature 1990;343(6259):659-661.
48. Deayton JR, Prof Sabin CA, Johnson MA, et al. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active anti-retroviral therapy. Lancet 2004;363(9427):2116-2121. (Pubitemid 38844151)
49. King CA, Baillie J, Sinclair JH. Human cytomegalovirus modulation of CCR5 expression on myeloid cells affects susceptibility to human immunodeficiency virus type 1 infection. J Gen Virol 2006;87(Pt 8):2171-2180. (Pubitemid 44178095)
50. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184(3):1101-1109. (Pubitemid 26313567)
51. Bleul CC, Schultze JL, Springer TA. B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. J Exp Med 1998;187(5):753-762. (Pubitemid 28115191)
52. McLeod SJ, Li AH, Lee RL, Burgess AE, Gold MR. The Rap GTPases regulate B cell migration toward the chemokine stromal cell-derived factor-1 (CXCL12): potential role for Rap2 in promoting B cell migration. J Immunol 2002;169(3):1365-1371. (Pubitemid 34809180)
53. De Falco E, Porcelli D, Torella AR, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004;104(12):3472-3482. (Pubitemid 39564415)
54. Abu El-Asrar AM, Struyf S, Van den Broeck C, et al. Expression of chemokines and gelatinase B in sympathetic ophthalmia. Eye (Lond) 2007;21(5):649-657. (Pubitemid 46730714)
55. Sonmez K, Drenser KA, Capone A Jr, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008;115(6):1065-1070 e1.
56. Fang IM, Yang CH, Lin CP, Yang CM, Chen MS. Expression of chemokine and receptors in Lewis rats with experimental autoimmune anterior uveitis. Exp Eye Res 2004;78(6):1043-1055.
57. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004;122(12):1801-1807. (Pubitemid 39602140)
58. Butler JM, Guthrie SM, Koc M, et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest 2005;115(1):86-93. (Pubitemid 40385508)
59. Yamaguchi A, Ikeda Y, Hirai T, Fujikawa T, Morita I. Local changes of IGF-I mRNA, GH receptor mRNA, and fiber size in rat plantaris muscle following compensatory overload. Jpn J Physiol 2003;53(1):53-60. (Pubitemid 36504328)